A novel therapeutic target for DM are incretin-based therapies, glucagon-like peptide-1 (GLP-1), and gastric-inhibitory-polypeptide (GIP) are released from the gastrointestinal tract (GIT) and act on the beta cell of pancreatic islets by increasing the secretion of insulin
Mayhew DL, Kim JS, Cross JM, Ferrando AA, Bamman MM (2009) Translational signaling responses preceding resistance training-mediated myofiber hypertrophy in young and old humans
Calming Redness and Soothing Sensitive Skin
Natnect and KetoZest are tapping into ketogenic formats and anti-nausea blends, aligned with consumer-reported side effects of GLP-1 drugs
L-Carnitine: Do You Even Need Them
We look at the clinical evidence [] Read More Relevant articles Helpful Links Copyright 2024 Bay Aesthetics